Who are PL 1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cordarone, metoprolol, amiodarone, Minoxidil Topical, Minoxidil 5% Topical Solution, Amiodarone i.v., Desflurane Inhalant Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pl-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

PL 1 — Competitive Intelligence Brief

PL 1 (PL 1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiarrhythmic. Area: Cardiovascular.

marketed Antiarrhythmic Potassium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

PL 1 (PL 1) — Technical University of Munich. PL 1 is a medication used to treat atrial fibrillation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PL 1 TARGET	PL 1	Technical University of Munich	marketed	Antiarrhythmic	Potassium channels
Cordarone	AMIODARONE	Pfizer	marketed	Antiarrhythmic	sodium channels, potassium channels, calcium channels	1985-01-01
metoprolol, amiodarone	metoprolol, amiodarone	Kuopio University Hospital	marketed	Beta-1 selective adrenergic antagonist; Class III antiarrhythmic	Beta-1 adrenergic receptor; Potassium channels (hERG and others)
Minoxidil Topical	Minoxidil Topical	Dr. dr. Lili Legiawati, SpKK(K)	marketed	Potassium channel opener	ATP-sensitive potassium channels
Minoxidil 5% Topical Solution	Minoxidil 5% Topical Solution	Triple Hair Inc	marketed	Potassium channel opener	ATP-sensitive potassium channels (KATP)
Amiodarone i.v.	Amiodarone i.v.	Charles University, Czech Republic	marketed	Class III antiarrhythmic agent	Potassium channels (hERG); also sodium channels, beta-adrenergic receptors, and calcium channels
Desflurane Inhalant Product	Desflurane Inhalant Product	Sichuan Provincial People's Hospital	marketed	Volatile inhalational anesthetic	GABA receptors, NMDA receptors, potassium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiarrhythmic class)

Pfizer · 3 drugs in this class
National Taiwan University Hospital · 2 drugs in this class
Boehringer Ingelheim · 1 drug in this class
Cliniques universitaires Saint-Luc- Université Catholique de Louvain · 1 drug in this class
Eli Lilly · 1 drug in this class
MTI Medical Private Limited, Pakistan · 1 drug in this class
Technical University of Munich · 1 drug in this class
· 1 drug in this class
Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class
Ain Shams University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PL 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/pl-1. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab